• Notifications
    This feature only available to registered users.
  • Alerts
    This feature only available to registered users
  • Welcome Guest!
  • Login Signup

Stock [ BUY ] / [ SELL ] Trading Strategies
. [ Show Details ]

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

CLSN [ Celsion Corp ]
Last Trade 0.7254 Date 9/30/2020
Change % -0.88 % Price Change -0.01
Open 0.7365 52 Week High 6.5
High 0.75 52 Week Low 0.6865
Low 0.7159 Type stock
Volume 447821 Average Volume 2590887
Prev Close 0.7318 Stock Exchange NASDAQ
Bid 0.7254 Ask 0.7345
Bid Size 1 Ask Size 33
1st Yr Estimated EPS Growth -0.5706 2nd Yr Estimated EPS Growth -0.0794
2 Years Forward Earning Yield -0.3963 2 Years Forward PE Ratio
2 Years EV/Forward EBIT -0.6209 2 Years EV/Forward EBITDA
Book Value per Share 0.7145 Book Value Yield 0.9764
Buy Back Yield CAPE Ratio
Cash Return -1.5668 Cash Flow per Share -0.696
Cash Flow Yield -0.9511 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.9839 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT -0.6497 EV / Forward EBITDA
EV / Forward Revenue 42.7521 EV / Pre Tax Income
EV / Revenue 21.376 EV / Total Asset 0.2288
Expected Dividend Growth Rate Free Cash Flow per Share -0.6998
Free Caash Flow Ratio Free Cash Flow Yield -0.9563
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.4304 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 1.024198 PB Ratio 10 Year Growth -0.248568
PB Ratio 3 Year Growth 3.30686 Cash Ratio 3 Year Average 431.3548
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 23.532935 PE Ratio 10 Year Growth
PE Ratio 10 Year High 27.666667 PE Ratio 10 Year Low 20.75
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg 23.532935
PE Ratio 5 Year Avg 23.532935 PE Ratio 5 Year High 27.666667
PE Ratio 5 Year Low 20.75 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.793279
Price to Cash Ratio 0.974389 Price / EBITDA
Price to Sales Ratio 37.894791 Price to Sales Ratio 10 Year Growth
Price to Sales Ratio 3 Year Avg 59.75738 Price to Sales Ratio 5 Year Avg 23.532935
Sale per Share 0.0193 Sales Yield 0.0264
Sustainable Growth Rate -0.8819 Tangible Book Value per Share 0.185
Tangible Book Value per Share 3 year Avg -0.4409 Tangible Book Value per Share 5 year Avg -2.1328
Total Asset per Share 1.379 Total Yield
Working Capital per Share 0.5192 Working Capital per Share 3 Year Avg 0.4057
Working Capital per Share 5 Year Avg 2.1404 Beta 2.197263
Company Profile

Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company is developing its lead product, ThermoDox that is in Phase III clinical trial for primary liver cancer; and in phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a license agreement with Yakult Honsha to commercialize and market ThermoDox for the Japanese market. The company also has a license agreement with Duke University under which it received exclusive rights to commercialize and use Duke's thermo-liposome technology. In addition, Celsion Corporation has a joint research agreement with Royal Phillips Electronics to evaluate the combination of Phillips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat a range of cancers. The company was founded in 1982 and is based in Columbia, Maryland.